Summarising evidence of associations of COVID-19 with a future diagnosis of inflammatory rheumatic and musculoskeletal diseases: a rapid review
Summarising evidence of associations of COVID-19 with a future diagnosis of inflammatory rheumatic and musculoskeletal diseases: a rapid review
Musculoskeletal symptoms are commonly reported following acute coronavirus disease 2019 (COVID-19). It is unclear whether those with musculoskeletal symptoms subsequently develop inflammatory rheumatic musculoskeletal disease (iRMD). This review seeks to identify evidence for an association between acute COVID-19 and subsequent iRMD diagnosis. A rapid review of the literature using a systematic search of Medline, EMBASE and two COVID-19 databases was undertaken until August 2022. Case studies, case series, cross-sectional, case-control, and cohort studies reporting patients with an incident iRMD following COVID-19 were included. Title and abstract screening were conducted by one reviewer, and full text screening by two reviewers. Data extraction and quality appraisal were by one reviewer, with a second verifying. Study-type specific critical appraisal tools were used. Results were narratively synthesised. 80 studies were included (69 case reports, 10 case series and 1 cross-sectional study). Commonly reported iRMDs were ‘reactive arthropathies’ (studies=47), ‘inflammatory arthropathies unspecified’ (studies=18), rheumatoid arthritis (studies=12) and lupus erythematosus (studies=11). The cross-sectional study reported 37% of those with COVID-19 developed ‘post-covid arthritis.’ Time from diagnosis of COVID-19 to iRMD presentation ranged from 0-120 days. Several mechanisms were proposed to explain the association between COVID-19 and iRMD development: auto-immune processes, aberrant inflammatory responses, colonisation of joint spaces, direct damage from the SARS-CoV2 virus and genetic predisposition. The level of evidence of the studies included in this review was low, and the quality generally poor. Prospective observational studies are required to confirm associations and likely impact of post COVID-19 iRMDs at a population level.
Mudge, Hannah R.
02925f30-cbaf-478d-9b4e-7b93bb614a79
Honey, Jonathan R.
03e7776e-332b-469c-a44a-421799e6bcb3
Tachoukaft, Sara
49b38827-cbde-47b7-b5f0-05ee19eaaea6
Hider, Samantha L.
80f07f31-0cd8-4da9-97e9-5f0abcfbe07c
Mason, Kayleigh J.
517457f6-e55c-4cc7-a1ed-b58007e99708
Welsh, Victoria K.
bc0b338a-12b7-4bfb-ae27-717e78d12ab4
Burton, Claire
28bd2d89-5eea-43f2-8e39-6326c7b8617e
Mudge, Hannah R.
02925f30-cbaf-478d-9b4e-7b93bb614a79
Honey, Jonathan R.
03e7776e-332b-469c-a44a-421799e6bcb3
Tachoukaft, Sara
49b38827-cbde-47b7-b5f0-05ee19eaaea6
Hider, Samantha L.
80f07f31-0cd8-4da9-97e9-5f0abcfbe07c
Mason, Kayleigh J.
517457f6-e55c-4cc7-a1ed-b58007e99708
Welsh, Victoria K.
bc0b338a-12b7-4bfb-ae27-717e78d12ab4
Burton, Claire
28bd2d89-5eea-43f2-8e39-6326c7b8617e
Mudge, Hannah R., Honey, Jonathan R., Tachoukaft, Sara, Hider, Samantha L., Mason, Kayleigh J., Welsh, Victoria K. and Burton, Claire
(2023)
Summarising evidence of associations of COVID-19 with a future diagnosis of inflammatory rheumatic and musculoskeletal diseases: a rapid review.
Arthritis Care & Research.
(In Press)
Abstract
Musculoskeletal symptoms are commonly reported following acute coronavirus disease 2019 (COVID-19). It is unclear whether those with musculoskeletal symptoms subsequently develop inflammatory rheumatic musculoskeletal disease (iRMD). This review seeks to identify evidence for an association between acute COVID-19 and subsequent iRMD diagnosis. A rapid review of the literature using a systematic search of Medline, EMBASE and two COVID-19 databases was undertaken until August 2022. Case studies, case series, cross-sectional, case-control, and cohort studies reporting patients with an incident iRMD following COVID-19 were included. Title and abstract screening were conducted by one reviewer, and full text screening by two reviewers. Data extraction and quality appraisal were by one reviewer, with a second verifying. Study-type specific critical appraisal tools were used. Results were narratively synthesised. 80 studies were included (69 case reports, 10 case series and 1 cross-sectional study). Commonly reported iRMDs were ‘reactive arthropathies’ (studies=47), ‘inflammatory arthropathies unspecified’ (studies=18), rheumatoid arthritis (studies=12) and lupus erythematosus (studies=11). The cross-sectional study reported 37% of those with COVID-19 developed ‘post-covid arthritis.’ Time from diagnosis of COVID-19 to iRMD presentation ranged from 0-120 days. Several mechanisms were proposed to explain the association between COVID-19 and iRMD development: auto-immune processes, aberrant inflammatory responses, colonisation of joint spaces, direct damage from the SARS-CoV2 virus and genetic predisposition. The level of evidence of the studies included in this review was low, and the quality generally poor. Prospective observational studies are required to confirm associations and likely impact of post COVID-19 iRMDs at a population level.
Text
Figure 1
- Author's Original
Restricted to Repository staff only until 23 August 2024.
Text
Supplementary Material
- Author's Original
Restricted to Repository staff only until 23 August 2024.
Text
Final_Manuscript_Clean (2)
- Accepted Manuscript
Restricted to Repository staff only until 23 August 2024.
More information
Accepted/In Press date: 23 August 2023
Identifiers
Local EPrints ID: 481828
URI: http://eprints.soton.ac.uk/id/eprint/481828
ISSN: 0893-7524
PURE UUID: de759453-2615-4d17-b29e-00941f6d9ac2
Catalogue record
Date deposited: 11 Sep 2023 16:33
Last modified: 17 Mar 2024 04:31
Export record
Contributors
Author:
Hannah R. Mudge
Author:
Jonathan R. Honey
Author:
Sara Tachoukaft
Author:
Samantha L. Hider
Author:
Kayleigh J. Mason
Author:
Victoria K. Welsh
Author:
Claire Burton
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics